ABBV vs. GKOS: A Head-to-Head Stock Comparison

Updated on October 6, 2025

Here’s a clear look at ABBV and GKOS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	ABBV	GKOS
Company Name	AbbVie Inc.	Glaukos Corporation
Country	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Health Care Equipment & Supplies
Market Capitalization	413.22 billion USD	5.01 billion USD
Exchange	NYSE	NYSE
Listing Date	January 2, 2013	June 25, 2015
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of ABBV and GKOS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. GKOS: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	ABBV	GKOS
5-Day Price Return	4.82%	7.54%
13-Week Price Return	23.58%	-15.55%
26-Week Price Return	11.64%	-11.19%
52-Week Price Return	18.84%	-31.96%
Month-to-Date Return	1.02%	7.19%
Year-to-Date Return	31.63%	-41.70%
10-Day Avg. Volume	6.76M	0.74M
3-Month Avg. Volume	5.66M	0.92M
3-Month Volatility	23.82%	38.86%
Beta	0.36	0.68

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

GKOS

-12.52%

Health Care Equipment & Supplies Industry

Max: 29.93%
Q3: 16.99%
Median: 9.28%
Q1: 5.10%
Min: -12.52%

GKOS has a negative Return on Equity of -12.52%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ABBV vs. GKOS: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.45%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

GKOS

-21.43%

Health Care Equipment & Supplies Industry

Max: 24.41%
Q3: 13.71%
Median: 10.08%
Q1: 5.96%
Min: -5.58%

GKOS has a negative Net Profit Margin of -21.43%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

ABBV vs. GKOS: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

ABBV

18.80%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

GKOS

-22.33%

Health Care Equipment & Supplies Industry

Max: 31.09%
Q3: 18.11%
Median: 15.07%
Q1: 8.48%
Min: -0.28%

GKOS has a negative Operating Profit Margin of -22.33%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

ABBV vs. GKOS: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

Symbol	ABBV	GKOS
Return on Equity (TTM)	95.59%	-12.52%
Return on Assets (TTM)	2.73%	-9.63%
Net Profit Margin (TTM)	6.45%	-21.43%
Operating Profit Margin (TTM)	18.80%	-22.33%
Gross Profit Margin (TTM)	70.93%	76.34%

Financial Strength

Current Ratio (MRQ)

ABBV

0.74

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

ABBV’s Current Ratio of 0.74 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

GKOS

5.51

Health Care Equipment & Supplies Industry

Max: 5.19
Q3: 3.00
Median: 2.13
Q1: 1.44
Min: 0.86

GKOS’s Current Ratio of 5.51 is exceptionally high, placing it well outside the typical range for the Health Care Equipment & Supplies industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

ABBV vs. GKOS: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

GKOS

0.09

Health Care Equipment & Supplies Industry

Max: 1.61
Q3: 0.76
Median: 0.45
Q1: 0.14
Min: 0.00

Falling into the lower quartile for the Health Care Equipment & Supplies industry, GKOS’s Debt-to-Equity Ratio of 0.09 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

ABBV vs. GKOS: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

GKOS

-28.92

Health Care Equipment & Supplies Industry

Max: 56.35
Q3: 25.56
Median: 9.60
Q1: 3.78
Min: -26.49

GKOS has a negative Interest Coverage Ratio of -28.92. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

ABBV vs. GKOS: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

Symbol	ABBV	GKOS
Current Ratio (MRQ)	0.74	5.51
Quick Ratio (MRQ)	0.48	4.52
Debt-to-Equity Ratio (MRQ)	49.22	0.09
Interest Coverage Ratio (TTM)	2.70	-28.92

Growth

Revenue Growth

ABBV vs. GKOS: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. GKOS: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

2.71%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ABBV’s Dividend Yield of 2.71% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

GKOS

0.00%

Health Care Equipment & Supplies Industry

Max: 4.15%
Q3: 1.76%
Median: 0.79%
Q1: 0.00%
Min: 0.00%

GKOS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ABBV vs. GKOS: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

226.84%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

GKOS

0.00%

Health Care Equipment & Supplies Industry

Max: 160.00%
Q3: 66.60%
Median: 27.49%
Q1: 0.00%
Min: 0.00%

GKOS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ABBV vs. GKOS: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

Symbol	ABBV	GKOS
Dividend Yield (TTM)	2.71%	0.00%
Dividend Payout Ratio (TTM)	226.84%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

111.05

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

At 111.05, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

GKOS

Health Care Equipment & Supplies Industry

Max: 67.29
Q3: 47.01
Median: 30.94
Q1: 23.91
Min: 10.79

P/E Ratio data for GKOS is currently unavailable.

ABBV vs. GKOS: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

7.16

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

ABBV’s P/S Ratio of 7.16 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

GKOS

11.67

Health Care Equipment & Supplies Industry

Max: 9.49
Q3: 5.41
Median: 2.86
Q1: 2.07
Min: 0.74

With a P/S Ratio of 11.67, GKOS trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

ABBV vs. GKOS: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

GKOS

7.71

Health Care Equipment & Supplies Industry

Max: 10.85
Q3: 6.56
Median: 3.53
Q1: 2.36
Min: 0.71

GKOS’s P/B Ratio of 7.71 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

ABBV vs. GKOS: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

Symbol	ABBV	GKOS
Price-to-Earnings Ratio (TTM)	111.05	--
Price-to-Sales Ratio (TTM)	7.16	11.67
Price-to-Book Ratio (MRQ)	261.01	7.71
Price-to-Free Cash Flow Ratio (TTM)	22.91	457.66